Medpace Holdings Stock News

Medpace supports the biopharmaceutical industry with state of the art research methods to accelerate the approval of drugs.

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 14,578 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The stock was sold at an average price of $213.26, for a total value of $3,108,904.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through []

Related Stocks: MEDP ,

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 14,578 shares of the stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $213.26, for a total value of $3,108,904.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. MEDP stock […]

Wells Fargo & Company MN lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 118,352 shares of the companys stock after selling 22,146 shares during the period. Wells Fargo & Company MNs holdings in Medpace were worth $20,904,000 at the end of []

Related Stocks: MEDP ,

CRO Services Market Key Players: Pharmaceutical Product, Development, LLC., Medpace, Clintec, IQVIA, PRA Health Sciences, ICON plc, KCR S.A.PSI, Parexel International Corporation., Covance, Other prominent players CRO Services Market Key Players: Pharmaceutical Product, Development, LLC., Medpace, Clintec, IQVIA, PRA Health Sciences, ICON plc, KCR S.A.PSI, Parexel International Corporation., Covance, Other prominent players

Harbor Investment Advisory LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 553 shares of the companys stock, valued at approximately $105,000. A number of other hedge funds have also recently []

Medpace Holdings, Inc. (NASDAQ:MEDP)s share price hit a new 52-week high on Friday . The stock traded as high as $230.91 and last traded at $229.48, with a volume of 1542 shares changing hands. The stock had previously closed at $226.27. A number of analysts have recently commented on MEDP shares. Zacks Investment Research raised []

Zymergen (NASDAQ:ZY) and Medpace (NASDAQ:MEDP) are both basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Analyst Ratings This is a summary of current recommendations for Zymergen and Medpace, as provided by MarketBeat.com. []

Medpace Holdings, Inc. (NASDAQ:MEDP) shares hit a new 52-week high during mid-day trading on Friday . The company traded as high as $230.91 and last traded at $229.48, with a volume of 1542 shares changing hands. The stock had previously closed at $226.27. A number of equities analysts recently issued reports on MEDP shares. Truist []

Equities research analysts expect Medpace Holdings, Inc. (NASDAQ:MEDP) to announce earnings of $1.25 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Medpaces earnings. The lowest EPS estimate is $1.22 and the highest is $1.27. Medpace posted earnings of $1.39 per share during the same quarter last []

Bank of America Corp DE grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 133,121 shares of the companys stock after buying an additional 2,124 shares during the quarter. Bank of America Corp DE owned []

Beacon Pointe Advisors LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,130 shares of the companys stock after selling 118 shares during the period. Beacon Pointe Advisors LLCs holdings in Medpace were []